first
diagnos
china
novemb
sar
document
approxim
person
global
death
canada
probabl
suspect
case
march
juli
death
reflect
mortal
rate
spread
sar
shown
airborn
droplet
result
acut
pulmonari
inflamm
epitheli
damag
determin
novel
coronaviru
sarscov
etiolog
agent
sar
base
phylogenet
sequenc
analysi
best
fit
within
group
coronavirus
includ
mous
hepat
virus
mhv
infect
sar
vari
consider
term
clinic
sever
variat
almost
certainli
due
populationbas
divers
gene
control
immun
respons
clearanc
mous
hepat
viru
coincid
robust
innat
immun
respons
includ
increas
number
cell
diseas
death
correl
high
viral
titer
suggest
diseas
reflect
alter
host
innat
immun
respons
furthermor
host
product
respons
type
interferon
ifn
key
determin
outcom
mhvinfect
mice
howev
ifn
cytokin
regul
coordin
manner
inflamm
charact
specif
immun
respons
imbal
time
proport
cellular
respons
inflammatori
cytokin
viral
infect
lead
chronic
diseas
death
although
number
model
sar
propos
includ
sarscov
infect
mice
cat
ferret
sarscov
infect
nonhuman
primat
none
model
produc
lung
patholog
similar
seen
human
serv
model
agent
includ
neutral
antibodi
put
vaccin
antivir
studi
effect
viral
replic
first
isol
mice
infect
massiv
hepat
necrosi
autopsi
analysi
realiz
infect
mice
coinfect
eperythrozoon
coccoid
mice
infect
devoid
bacterium
mild
hepat
seen
mice
surviv
describ
mous
model
establish
laboratori
offer
potenti
provid
insight
pathogenesi
mhvinduc
lung
injuri
contribut
viru
host
immun
respons
mice
femal
balbcj
aj
mice
week
age
purchas
jackson
laboratori
hous
anim
facil
toronto
gener
research
fed
standard
laboratori
chow
diet
water
ad
libitum
viru
mhvjhm
mhv
origin
obtain
american
type
cultur
collect
atcc
plaqu
purifi
monolay
dbt
cell
titer
cell
use
standard
plaqu
assay
tissu
process
lung
spleen
liver
kidney
small
intestin
heart
brain
harvest
mice
sampl
snap
frozen
store
c
freezer
fix
formalin
analysi
detect
fibrin
standard
immunohistochem
system
employ
previous
describ
cytokin
assay
serum
cytokin
level
assay
use
commerci
cytometr
bead
array
kit
bd
bioscienc
sampl
analyz
triplic
use
bd
fac
calibur
flow
cytomet
balbcj
mice
infect
pfu
intranas
develop
sever
pulmonari
diseas
character
congest
pulmonari
infiltr
hyalin
membran
hemorrhag
addit
diffus
pulmonari
infiltr
focal
deposit
fibrin
seen
around
small
arteri
blood
vessel
alveolar
space
entrap
platelet
chang
note
earli
day
pi
progress
day
clinic
mice
becam
letharg
rapid
respir
mice
surviv
pulmonari
patholog
resolv
within
day
infect
balbcj
mice
infect
intranas
mhvjhm
develop
neither
liver
lung
patholog
although
produc
pulmonari
lesion
milder
gener
characterist
lesion
caus
sar
infect
mice
develop
sever
hepat
necrosi
die
liver
failur
day
thu
strain
mhv
repres
relev
model
sar
tabl
data
suggest
induc
patholog
similar
human
sar
therefor
infect
inbr
strain
mice
aj
mice
previous
known
show
vari
degre
suscept
strain
mhv
although
develop
acut
pulmonari
diseas
mice
surviv
pulmonari
lesion
resolv
day
mice
show
intermedi
pattern
resistancesuscept
mice
die
day
surviv
mice
develop
pulmonari
fibrosi
bronchial
hyperplasia
figur
aj
mice
die
within
day
infect
sever
pulmonari
diseas
lung
show
consolid
pneumon
hyalin
membran
fibrin
deposit
lymphocyt
macrophag
infiltr
figur
examin
lung
tissu
suscept
aj
resist
mice
presenc
mrna
transcript
realtim
pcr
protein
fibrin
known
caus
thrombosi
shown
figur
protein
express
inflammatori
cell
type
pneumocyt
juxtaposit
deposit
fibrin
lung
balbcj
mice
neither
fibrin
deposit
electron
micrograph
lung
show
virion
mostli
local
type
pneumocyt
pulmonari
macrophag
data
shown
plaqu
assay
viru
detect
lung
hour
reach
maxim
level
hour
aj
mice
persist
high
level
death
anim
viru
also
detect
lung
mice
hour
pi
reach
maxim
level
day
disappear
day
pi
serum
collect
aj
mice
pre
post
infect
cytokin
measur
tabl
gene
express
level
differ
assess
lung
tissu
infect
aj
mice
use
quantit
realtim
pcr
contrast
late
hr
postinfect
low
level
induct
aj
mice
observ
robust
sustain
ifn
exist
model
sar
rodent
nonhuman
primat
fail
produc
lung
patholog
mortal
similar
seen
human
thu
model
serv
assess
effect
agent
includ
neutral
antibodi
put
vaccin
antivir
viral
replic
model
describ
report
produc
clinic
syndrom
mice
serv
model
sar
first
found
produc
straindepend
diseas
interestingli
aj
mice
usual
resist
infect
die
intranas
infect
contrast
although
balbcj
mice
develop
pulmonari
diseas
anim
clear
viru
day
surviv
mice
develop
intermedi
pattern
suscept
mortal
viral
titer
higher
suscept
aj
mice
serum
cytokin
chemokin
markedli
elev
mice
comparison
resist
anim
find
consist
elev
level
detect
sera
sar
patient
elev
cytokin
chemokin
could
contribut
immunopatholog
sar
fact
corticosteroid
amelior
diseas
sar
patient
consist
previous
report
induc
inflammatori
immun
coagul
result
fibrin
deposit
hepat
necrosi
model
sar
mrna
transcript
protein
also
seen
associ
deposit
fibrin
diseas
lung
aj
mice
suggest
inflammatori
mediat
may
contribut
pathogenesi
sar
well
result
compat
report
human
sar
cov
suscept
anim
fail
gener
robust
type
interferon
respons
addit
antivir
effect
known
inhibit
inflammatori
cytokin
ifn
alfacon
treatment
sar
patient
acceler
resolut
inflamm
possibl
contribut
increas
surviv
consist
observ
thu
collect
data
support
concept
pathogenesi
sar
reflect
alter
innat
immun
respons
mark
inflamm
molecular
mechan
find
present
known
model
offer
potenti
conduct
addit
studi
provid
insight
pathogenesi
coronavirusinduc
lung
injuri
contribut
viru
host
immun
respons
anticip
data
gener
studi
provid
novel
insight
pathogenesi
seriou
human
diseas
provid
avenu
therapi
work
support
canadian
institut
health
research
grant
